Commentary

Video

Poised Potential With Zenocutuzumab in NRG1+ Pancreatic Cancer

E. Gabriela Chiorean, MD, of Fred Hutch Cancer Center, discusses the recent clinical data with zenocutuzumab in patients with NRG1 fusion–positive pancreatic cancer and the impact the approval of this agent could have on the landscape.

Related Videos
Tilak Sundaresan, MD
Nicole S. Evans, MD
Rocio Garcia-Carbonero, MD
Mazyar Shadman, MD, MPH
Petros Grivas, MD, PhD
E. Gabriela Chiorean, MD
E. Gabriela Chiorean, MD
E. Gabriela Chiorean, MD
Brandon Huffman, MD
Suneel Kamath, MD